The EORTC Soft Tissue and Bone Sarcoma Group (STBSG) develops, stimulates, and coordinates studies on all aspects of sarcomas, and over the years they have made significant achievements in the research and treatment of sarcomas. Through EORTC trials 62001, 62005, 62024, and 62063, they established imatinib in the treatment of gastrointestinal stromal tumors (GIST). Because the STBSG has conducted a large number of clinical trials in advanced disease and collected and stored all trial data in a consistent format, they were able to use these data in retrospective studies and develop progression-free survival as the primary endpoint for phase II studies in advanced soft-tissue sarcoma. This database also served as a basis for research projects analyzing subgroups of tumors like malignant peripheral nerve sheath tumors, and for exploring prognostic and predictive factors for first-line chemotherapy including ifosfamide, and proved to be of value when analyzing the results of adjuvant chemotherapy in adolescents and young adults as compared to the adult patient population. This article describes these achievements and looks into the future strategy of the STBSG.
Introduction
The objectives of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) are to develop, stimulate and coordinate studies on all aspects of sarcomas within the framework of the EORTC. This is done by organizing clinical trials and regular investigator meetings as well as conferences and symposia to promote such studies. At present, STBSG has 54 member institutions from 14 countries. It is an interdisciplinary group with medical oncologists, radiation oncologists, surgical oncologists, trial. 1 The group conducted the largest study to compare single-agent doxorubicin versus doxorubicin plus ifosfamide as first-line therapy for metastatic soft-tissue sarcoma (EORTC trial 62012). The role of limited dose of radiation therapy in aggressive fibromatosis/desmoids, a very rare subset of sarcoma patients, was studied and will report soon after long-term follow up (EORTC trial 62991). The group also conducted the largest translational research project worldwide in radiation-induced sarcomas (TR01/01). As a more 'classical' approach, the group conducted over 20 phase I and phase II trials to evaluate many individual drugs and drug combinations to analyze response and survival in advanced sarcoma.
There are three major aspects of these trials that deserve closer attention.
Imatinib in gastro-intestinal stromal tumors (GIST)
Everybody is aware of the dramatic improvement in overall survival (OS) in patients with metastatic GIST since imatinib became available, and the STBSG was involved in the development of this drug from the very beginning. A phase I study was conducted to identify the dose-limiting effects in patients with advanced soft-tissue sarcomas including GIST and showed that a dose of 400 mg twice daily was well tolerated with diminishing side-effects during continuous treatment. CT scans revealed that major regression of the tumor was induced and FDG-uptake was dramatically decreased. More than three fourths of the patients were still on treatment after more than 9 months which was a unique result of a phase I study, 2 and a later update of the study showed that more than 80% of the patients had clinically important benefit which changed the treatment landscape dramatically (Fig. 1) . The phase II study (EORTC trial 62001) followed immediately and showed that in a chemotherapy pretreated group of patients suffering from advanced GIST and softtissue sarcoma, the GIST patients benefitted greatly with 73% of the patients being free from progression at one year. 3 In contrast, there were no objective responses in the other soft-tissue sarcoma group. The conclusion still holds today that the dose of 800 mg imatinib is highly active in patients with KIT-positive GIST, but patients with other soft-tissue sarcomas unselected for a molecular target are unlikely to benefit. Concurrent with 62001 a randomised phase II study in the USA, B2222, treated GIST patients with either 400 mg or 600 mg daily and similar activity was reported. 4 The STBSG, joined by the Australasian Gastro-Intestinal Trials Group (AGITG) and the Italian Sarcoma Group performed a phase III study (EORTC trial 62005), comparing 400 mg versus 800 mg of imatinib, and 946 patients from 13 countries were recruited in less than a year! The STBSG selected to use progression-free survival (PFS) as the primary endpoint of this study, whereas the NorthAmerican trial looked at OS as the primary endpoint and recruited 746 patients. In study 62005 there was no significant difference in response to treatment according to imatinib dose, however, the higher 800 mg dose achieved significantly longer PFS. 5 Our studies suggested that the PFS benefit was largely derived from patients with the rare exon 9 mutation in KIT. 6 While this difference was not apparent in the North-American study, which had a much smaller number of exon 9 mutant patients, a meta-analysis of both the EORTC 62005 and S0033 data sets confirmed the significantly improved PFS seen in the exon 9 patients using the 800 mg dose, while no such effect was seen in the patients with exon 11 mutations. Consequently, the treatment starting dose for imatinib is 400 mg in all patients except those with tumors harboring exon 9 mutations, who require 800 mg of imatinib for optimal benefit. 7 The molecular data of the study using pretreatment samples were analyzed for mutations of KIT and PDGFR-a and the mutation types were correlated with the survival data of the patients. It turned out that the exon 9 activating mutation of KIT was the strongest adverse prognostic factor for response, including a relative risk of progression of 171% when compared to exon 11 mutations. 6, 8 Those patients profited from the high-dose regimen with a significantly improved PFS rate and a reduction of the relative risk to a hazard ratio of 0.61. This study for the first time concluded that in a solid tumor the genotype is of major prognostic significance for PFS and OS. Molecular data as well as immunohistochemistry were used to analyze the effect of the immuno-histochemical phenotype of the tumor on PFS or OS, but did not show any correlations. 9 However, the study material contributed to the evaluation of a new marker (DOG1) in GIST and proved that a combination of CD117 and DOG1-immunostaining is sufficient to confirm the histological diagnosis of a GIST and separate it from other spindle cell malignancies. 10 A tissue microarray project on 353
samples from the phase III study was used to analyze the expression pattern of cell cycle and apoptosis regulators. Impaired p53, p16, BCL2, and CHK2 expression was common in advanced GIST and cell cycle/apoptosis maintenance is instrumental for optimal response to imatinib.
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Further studies focused on determinants of imatinib efficacy. A thorough analysis of pharmacokinetics revealed a trend towards increased imatinib clearance after chronic exposure of more than 12 months. 12 There was no effect of cigarette smoking on the pharmacokinetics of imatinib, however, smokers with GIST showed a shorter OS and time to progression. 13 Further studies addressed a concern that imatinib might be cardiotoxic, showing that only 0.2% of the patients after nearly 25,000 exposures had possible cardiac side-effects. 14 An analysis of the correlation between toxicities of CTC grade II or more with imatinib dose, age, sex, performance status, disease site, and size of lesions at trial entry led to a multivariate risk calculator that can be used in the clinics for individual patients and is available at the EORTC website. 15 Also, different prognostic factors for initial and late resistance to imatinib in advanced GIST could be evaluated. 16 Very important was the report on the analysis whether tumor response to imatinib contributes to a better survival in comparison to patients achieving "just" stable disease, as might be claimed with cytotoxic chemotherapy. However, in the treatment of GIST with imatinib, it did not matter whether patients developed a CR, PR, or MR, or even no change; all treatment responses resulted in similar PFS and OS. After 6 months of imatinib, responders by RECIST had the same survival outcome as patients classified as stable disease. Only patients experiencing progressive disease had significantly worse outcome. 17 These findings are of major importance in accepting PFS as a primary endpoint in patients with soft-tissue sarcoma in the metastatic setting when treated with tyrosine kinase inhibitors. Following the development of the drug in metastatic patients, STBSG also started the largest adjuvant study in patients with intermediate and high-risk GIST (EORTC trial 62024) comparing two years of treatment versus observation. Unfortunately, the usual primary endpoint for an adjuvant trial, OS, turned out to be problematic. Treatment for metatastic GIST after relapse from prior adjuvant therapy can successfully salvage the majority of patients and it could take more than 10 years until the primary endpoint is evaluable. After recruiting more than 900 patients to this study, the primary endpoint has been changed to 'time to imatinib failure' in those patients who received imatinib in the adjuvant setting and subsequently again on progression, to provide an earlier readout of treatment benefit. The group was deeply involved in the discussion on how to interpret the data of the ACOSOG Z9001 adjuvant study showing that one year of imatinib significantly improved PFS but did not translate into an improvement of OS, at least partly because of unblinding and cross-over, and probably represents under-treatment for patients with a high risk of recurrence. 18 In a joint effort with the EU-funded network Conticanet, the reporting tools on the surgery for the primary tumor were evaluated by thoroughly comparing the source data of the original operative record and the original pathology report with the data used for patient study entry. STBSG has constructed a reporting tool to enable adequate documentation of the initial findings and measures which is now available for other study groups. 19 In continuing the evaluation of imatinib, STBSG in collaboration with SWOG proved the efficacy of the drug in an extremely rare sarcoma subtype, dermatofibrosarcoma protuberans, by pooling the data of two separate phase II-studies. Again, the molecular target of a translocation t [17;22] involving the PDGFR-b gene is the decisive element for imatinib treatment success. 
Developing PFS as a primary endpoint in trials
Only a few cytotoxic agents have demonstrated activity against advanced soft-tissue sarcoma (e.g. doxorubicin, ifosfamide, dacarbazine); in most cases, the treatment is palliative, and only 8% of patients are still alive 5 years after start of first-line chemotherapy. Most of the confirmed and investigational anticancer agents studied in the last 50 years have been explored in soft-tissue sarcoma, but few have shown any substantial activity in terms of objective responses. 21 However, a few drugs (e.g. trabectedin) have induced some unexpected long disease stabilizations. One of the explanations for those disappointing (but not completely negative) results may lie in the large heterogeneity of soft-tissue sarcoma, in terms of histology (the current classification includes more than 50 histological subtypes) and anatomic presentation (virtually all sites of the human body). Another explanation may be the traditional choice of objective response to therapy (documentation of a decrease in tumor load) as primary endpoint for drug screening studies, which does not reflect the mechanism of action of cytostatic agents. Endpoints based on disease stabilization rather than objective responses are obviously more appropriate for those agents, but cut-off values would be needed to distinguish active from non-active drugs. Indeed, if the tumor size has not objectively increased after a predefined time period, this can be due either to the activity of the drug or simply to the slow growth of the original tumor. Therefore, a small proportion of disease stabilizations (according to standard criteria, like WHO or RECIST) is to be expected, even with inactive agents or combinations, while the expected proportion of objective responses is close to zero. The STBSG has conducted a large number of clinical trials in advanced disease and collected and stored all trial data in a consistent format. The histology of most cases has been reviewed by an international panel of experts. Consequently, the group has accumulated a database of more than 3000 patients which can be used for retrospective studies. We have proposed to use the progression-free status at a fixed time point (3 or 6 months after treatment start) as the primary endpoint for phase II studies in advanced soft-tissue sarcoma 22 ( Fig. 2) . To use this criterion we need estimates in the studied patient population of the proportion of patients still expected to be progression-free after treatment with an inactive agent and after treatment with an active agent or regimen (reference values for the statistical design). Those two proportions should be different enough to limit the sample size of the trial (preferably at least 15% apart). We have used the STBSG database to estimate this proportion in various groups of patients.
For patients treated after failure of the first-line chemotherapy regimen, we used the data from 12 STBSG clinical trials, including 146 patients treated with an active regimen (ifosfamide or dacarbazine), and 234 patients treated with an inactive regimen (nine investigational drugs); 39% of the patients from the first group were progression free after 3 months, while this figure was only 21% for patients of the second group. We concluded that the difference was large enough to use the 3-month progression-free rate as the primary endpoint to screen new agents used as 2nd-or 3rd-line therapy for advanced disease, and that the estimations of the progression-free rate with active and with inactive agents were precise enough (standard error <5%) to be used as reference values in classical phase II designs.
For patients treated with a first-line chemotherapy regimen, we used a database of 1154 patients, all treated with an active anthracycline-based regimen. The size of the database was sufficient to provide reference values for the principal histological subtypes; leiomyosarcoma (n = 531), MFH/NOS (n = 217), synovial sarcoma (n = 115), neurogenic sarcoma (n = 113), liposarcoma (n = 110), fibrosarcoma (n = 68). Estimations of the 6-month progression-free rates varied between 30% and 56% in the different subgroups, and between 44% and 77% for the 3-month progression-free rate; the standard error was 6% or less for all estimates.
Those reference values have become extremely useful for new drug screening. The success of imatinib mesylate in GIST has raised the hope that other targeted therapies could show activity in other types of sarcoma. As those drugs are essentially cytostatic, objective response to therapy is not an appropriate screening endpoint, and progression-free rate offers a valid alternative. This endpoint has been used by the STBSG to demonstrate the activity of pazopanib and of eribulin (EORTC trial 62052) 23 in phase II trials conducted in different histological subtypes of soft-tissue sarcoma and has resulted in the exclusion of certain sarcoma subtypes from subsequent phase III studies. However, a definitive demonstration of the therapeutic efficacy of new drugs still requires appropriate testing in comparative randomized phase III clinical trials, like the PALETTE trial (Phase III trial of pazopanib vs placebo in patients who had failed anthracycline-based therapy).
Exploiting the database of patients treated in group studies
The database described above was not only used to generate reference curves for PFS and OS in new drugs. It also served as a basis for research projects analyzing subgroups of tumors like malignant peripheral nerve sheath tumors (MPNST) in which the role of chemotherapy was unclear. 175 MPNST out of 2675 eligible STS patients were analyzed and it turned out that outcome was similar for MPNST versus other sarcoma subtypes. Performance status was an independent prognostic factor for OS and the chemotherapy regimen was an independent prognostic factor for response, with doxorubicin-ifosfamide producing the best response. 24 The database was also used to explore prognostic and predictive factors for first-line chemotherapy including ifosfamide. For this purpose, a retrospective, exploratory analysis was performed on data from 1337 advanced STS patients who received first-line ifosfamide-containing chemotherapy; 660 patients treated with doxorubicin monotherapy served as comparators. The study provided important information for the interpretation and design of clinical trials for specific sarcoma subtype entities and may contribute to further treatment individualisation of advanced STS patients. 25, 26 A very successful application of these criteria and the discrimination of active versus inactive drugs in second-line studies was used when developing pazopanib, a multikinase angiogenesis inhibitor. After the phase II study with the strata of liposarcoma, synovial sarcoma, leiomyosarcoma and 'other sarcoma subtypes' had shown that for liposarcoma patients the threshold of an active drug was not met (Fig. 3) , those patients were excluded from the subsequent and very successful phase III study.
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The database also proved to be of major value when analyzing the results of adjuvant chemotherapy in the adolescent and young adult (15−29 years, AYA population) versus the adult patient group ( 30 years). We conducted a retrospective study, pooling data from two randomized trials of adjuvant chemotherapy in STS (EORTC trial 62771 and 62931). A total of 793 patients were included with a median follow-up of 8.74 years. Patients' characteristics were globally similar with two exceptions: histological subtype and tumor size. Significant differences could be found concerning prognostic factors between the AYA population and older patients, and adjuvant chemotherapy was associated with improved RFS only in the older population, highlighting agespecific differences and prognostic information in this population. 28 
Future strategy of the group
Given the recent success of defining diagnostic and therapeutic targets in sarcoma, like the IGFR1-receptor in Ewing sarcoma, PDGFR-b in DFSP, or ALK/MET in alveolar soft-part sarcoma and inflammatory myofibroblastic tumors, a major part of the future strategy of STBSG is intensifying translational research. The EU FP7 funded networks of excellence Conticanet and EuroBonet were both headed by group officers (J.Y. Blay and P. Hoogendorn) and brought together a framework of research centers involving several group sites.
The recently founded EUROSARC consortium involves several group sites and will further develop a network of sarcoma centers mainly devoted to conducting studies in rare sarcoma subtypes where funding through pharmaceutical or biotechnology companies cannot be expected beyond the supply of drugs. A major grant has been received from the EU for these efforts in the field of rare cancer. Beyond pan-European collaboration, also translatantic (Sarcoma Alliance for Research through Collaboration, SARC) as well as transpacific cooperation is in place via the World Sarcoma Network (WSN) bringing together high-volume centers to enable trials for super rare sarcoma subtypes as well as creating research opportunities at the level of the Connective Tissue Oncology Society, CTOS.
Multimodality therapy of sarcoma is the mainstay for successful treatment of advanced tumors. The group provides educational tools like nomograms, surgical standards for the reporting of primary sarcoma or GIST resections but also teaching courses for sarcoma treatment.
The STBSG was founded by a group of mostly medical oncologists with the aim of improving the systemic treatment of sarcomas. It has subsequently evaluated novel techniques such as hyperthermia and is currently conducting a large phase III study evaluating the role of external beam radiation in the neoadjuvant setting prior to surgical therapy of retroperitoneal sarcomas. The role of the STBSG in identifying the value of imatinib in the treatment of GIST and other diseases and more recently the potential value of an anti-angiogenic tyrosine kinase inhibitor, pazopanib, is acknowledged worldwide. The innovative approaches to new drug evaluation and the insights provided by the database have been hugely influential. The group is continuously expanding its membership in the recognition that in the same way that the treatment of sarcomas is multidisciplinary, research must span not only the clinical disciplines but also related sciences such as genetics, biology, and biotechnology. Only by attracting basic scientists with an interest in sarcoma to work with us, will we be successful in advancing the science and ensuring that our clinical studies incorporate meaningful translational research. Recent meetings have demonstrated the range of scientific expertise within the Group and the enthusiasm to embrace novel scientific techniques to improve our understanding of these rare and fascinating diseases. Given the continuing discovery of new, relevant targets for sarcoma therapy, one can be optimistic that treatment will continue to advance and that the STBSG will continue to play a major role in this important project.
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